Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1997 1
1998 1
1999 3
2000 3
2002 2
2004 1
2005 1
2007 1
2009 1
2011 2
2012 1
2013 3
2014 1
2015 2
2016 1
2017 1
2018 1
2020 1
2021 2
2023 2
2024 2
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D. Cortes JE, et al. Leukemia. 2024 Jul;38(7):1522-1533. doi: 10.1038/s41375-024-02278-8. Epub 2024 May 16. Leukemia. 2024. PMID: 38755421 Free PMC article. Clinical Trial.
Asciminib targets the BCR::ABL1 myristoyl pocket, maintaining activity against BCR::ABL1(T315I), which is resistant to most approved adenosine triphosphate-competitive tyrosine kinase inhibitors. We report updated phase I results (NCT02081378) assessing safety/tolerability …
Asciminib targets the BCR::ABL1 myristoyl pocket, maintaining activity against BCR::ABL1(T315I), which is resistant to most approved aden …
Intravenous nicorandil versus adenosine for fractional flow reserve measurement: a crossover, randomized study.
Nishi T, Kitahara H, Fujimoto Y, Nakayama T, Nagashima K, Hanaoka H, Kobayashi Y. Nishi T, et al. Heart Vessels. 2018 Dec;33(12):1570-1575. doi: 10.1007/s00380-018-1197-2. Epub 2018 Jun 1. Heart Vessels. 2018. PMID: 29858919 Clinical Trial.
In this crossover randomized study, 49 patients underwent FFR measurement with a consecutive randomized order of patient-blind infusions of continuous IV adenosine administration and a single bolus IV administration of nicorandil. The primary endpoint was the difference be …
In this crossover randomized study, 49 patients underwent FFR measurement with a consecutive randomized order of patient-blind infusions of …
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.
Cortes JE, Lang F, Rea D, Hochhaus A, Breccia M, Goh YT, Heinrich MC, Hughes TP, Janssen JJWM, le Coutre P, Minami H, Sasaki K, DeAngelo DJ, Sanchez-Olle G, Pognan N, Cao M, Hoch M, Mauro MJ. Cortes JE, et al. Leukemia. 2025 May;39(5):1124-1134. doi: 10.1038/s41375-025-02592-9. Epub 2025 Apr 9. Leukemia. 2025. PMID: 40204896 Free PMC article. Clinical Trial.
Data from in vitro and animal studies suggest that asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), synergizes with adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors (TKIs) to prevent emergence of and ov …
Data from in vitro and animal studies suggest that asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pock …
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study.
Hughes TP, Saglio G, Geissler J, Kim DW, Lomaia E, Mayer J, Turkina A, Kapoor S, Cardoso AP, Nieman B, Quenet S, Cortes JE. Hughes TP, et al. J Hematol Oncol. 2024 Dec 18;17(1):125. doi: 10.1186/s13045-024-01642-6. J Hematol Oncol. 2024. PMID: 39696526 Free PMC article. Clinical Trial.
This unique mechanism of action allows asciminib to be combined with adenosine triphosphate-competitive tyrosine kinase inhibitors to prevent resistance and enhance efficacy. ...
This unique mechanism of action allows asciminib to be combined with adenosine triphosphate-competitive tyrosine kinase inhibitors to …
Cardioprotective effects of oral nicorandil use in diabetic patients undergoing elective percutaneous coronary intervention.
Shehata M. Shehata M. J Interv Cardiol. 2014 Oct;27(5):472-81. doi: 10.1111/joic.12142. Epub 2014 Aug 30. J Interv Cardiol. 2014. PMID: 25174952 Free article. Clinical Trial.
OBJECTIVE: This study sought to evaluate the cardioprotective role of oral nicorandil (a hybrid between the nitrates and adenosine triphosphate [ATP] sensitive potassium channel activators) in diabetic patients undergoing elective percutaneous coronary intervention (PCI). …
OBJECTIVE: This study sought to evaluate the cardioprotective role of oral nicorandil (a hybrid between the nitrates and adenosine tr …
Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study.
Drago F, Ciccarese G, Cogorno L, Calvi C, Marsano LA, Parodi A. Drago F, et al. Eur J Dermatol. 2017 Aug 1;27(4):382-385. doi: 10.1684/ejd.2017.3025. Eur J Dermatol. 2017. PMID: 28468736 Clinical Trial.
Nicotinamide is the precursor of nicotinamide adenine dinucleotide (NAD+), an essential cofactor for adenosine triphosphate (ATP) production. It has recently been reported to be effective in reducing the rates of new non-melanoma skin cancers (NMSCs) and actinic keratosis …
Nicotinamide is the precursor of nicotinamide adenine dinucleotide (NAD+), an essential cofactor for adenosine triphosphate (ATP) pro …
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Stemmer SM, Benjaminov O, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, Patoka R, Singer B, Kerns WD, Fishman P. Stemmer SM, et al. Oncologist. 2013;18(1):25-6. doi: 10.1634/theoncologist.2012-0211. Epub 2013 Jan 8. Oncologist. 2013. PMID: 23299770 Free PMC article. Clinical Trial.
BACKGROUND: The A(3) adenosine receptor (A(3)AR) is overexpressed in the tumor and in the peripheral blood mononuclear cells of patients with hepatocellular carcinoma (HCC). ...
BACKGROUND: The A(3) adenosine receptor (A(3)AR) is overexpressed in the tumor and in the peripheral blood mononuclear cells of patie …
Influence of caffeine intake on intravenous adenosine-induced fractional flow reserve.
Kasumi I, Fujii K, Satoru O, Shin T, Katsuyuki H, Hiroto T, Rui I, Shingo Y, Sho N, Wataru Y, Hirofumi K, Yusuke T, Mikio K, Yuji S, Yorihiko H. Kasumi I, et al. J Cardiol. 2020 Nov;76(5):472-478. doi: 10.1016/j.jjcc.2020.05.011. Epub 2020 Jun 10. J Cardiol. 2020. PMID: 32532583 Free article. Clinical Trial.
BACKGROUND: This study evaluated whether caffeine abstention is required before fractional flow reserve (FFR) measurement by intravenous adenosine triphosphate (ATP) administration in Japanese patients. METHODS: This study was a subanalysis of a previously published study …
BACKGROUND: This study evaluated whether caffeine abstention is required before fractional flow reserve (FFR) measurement by intravenous …
36 results